Generic NIACIN INN equivalents, drug patent expiry and freedom to operate

Sponsor	Phase
Yale University	PHASE2
National Center for Complementary and Integrative Health (NCCIH)	PHASE2
Brigham and Women's Hospital	PHASE1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	NIASPAN	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-004	Jul 28, 1997		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	NIACIN	niacin	TABLET;ORAL	083136-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Abbvie	NIASPAN	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-001	Jul 28, 1997		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	NIASPAN	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-002	Jul 28, 1997	⤷ Start Trial	⤷ Start Trial
Abbvie	NIASPAN	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-002	Jul 28, 1997	⤷ Start Trial	⤷ Start Trial
Abbvie	NIASPAN TITRATION STARTER PACK	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-005	Jul 28, 1997	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Last updated: February 2, 2026

Executive Summary

Niacin (Vitamin B3), a water-soluble vitamin essential for human health, has historically played a vital role in cardiovascular health management and nutritional supplementation. The global market for niacin and its derivatives is driven by factors such as increasing prevalence of cardiovascular diseases (CVD), aging populations, expanding dietary supplement markets, and the development of pharmaceutical formulations for dyslipidemia. However, regulatory environments, evolving treatment paradigms, and competition from alternative therapies influence market expansion and profitability. This report analyzes current market dynamics, key drivers and restraints, emerging trends, and performs a financial trajectory assessment for niacin-based pharmaceuticals.

1. Market Overview

Aspect	Details
Estimated Global Market Size (2022)	USD 1.2 billion (including sales of niacin supplements and pharmaceuticals)
Compound Annual Growth Rate (CAGR)	4.5% (2022-2027 projection)
Major Regions	North America (45%), Europe (20%), Asia-Pacific (25%), Rest of World (10%)
Key Applications	Dietary supplements, pharmaceutical formulations for dyslipidemia, dermatology, neurological uses

2. Key Market Drivers

a. Rising Incidence of Cardiovascular Disease (CVD)

Global CVD prevalence (WHO, 2021): 523 million cases.
Niacin's pharmacological roles in modulating lipid profiles—reducing LDL-cholesterol, triglycerides, and increasing HDL-cholesterol—remain pivotal in CVD management.
Indication-specific formulations like extended-release niacin remain prevalent, especially in developed markets.

b. Aging Population and Increasing Nutritional Supplement Demand

Senior populations (≥65 years) represent 10-15% of global populations and are at higher risk of dyslipidemia.
Growing consumer awareness about dietary supplements propels over-the-counter products containing niacin.

c. Development of Novel Formulations and Combination Therapies

Innovations include controlled-release, extended-release, and combination drugs (e.g., niacin + statins).
These formulations aim to improve tolerability and adherence.

d. Regulatory Landscape

The FDA approves niacin formulations primarily for hyperlipidemia management.
Regulatory scrutiny on side effects (e.g., flushing, hepatotoxicity) influences product development.

3. Major Market Restraints

a. Side-Effect Profile Limiting Usage

Flushing, hepatotoxicity, and gastrointestinal discomfort limit patient compliance and market growth.
Recent guidelines prioritize statins and PCSK9 inhibitors over niacin, reducing prescription rates.

b. Competitive Landscape of Lipid-Modifying Agents

Competitors	Market Share (2022)	Notes
Statins	65%-70%	First-line therapy for hyperlipidemia
PCSK9 Inhibitors	10%-15%	Used in statin-intolerant or resistant patients
Niacin and Derivatives	5%-10%	Declining due to side-effects and competition

c. Patent and Regulatory Barriers

Limited patent protections for existing formulations restrict profit margins.
Genericization further reduces revenues for branded products.

4. Emerging Trends and Opportunities

a. Market Segmentation by Formulation

Formulation Type	Market Share (2022)	Growth Forecast (2022-2027)	Specifics
Immediate-release niacin	60%	Declining	Associated with higher flushing
Extended-release niacin	30%	Steady	Lower flushing, better compliance
Combination therapies	10%	Rapid growth	Niacin + statins or other lipid agents

b. Geographic Expansion into Emerging Markets

Growing middle class and healthcare infrastructure in APAC and Latin America.
Potential for over-the-counter (OTC) sales boosts.

c. Innovations in Formulation and Delivery

Liposomal and nanoemulsion delivery systems aim to reduce side-effects.
Research into plant-based and bio-fermented niacin variants.

d. Strategic Collaborations and Licensing

Pharma companies are pursuing licensing deals for novel formulations.
Mergers and acquisitions shaping the competitive landscape.

5. Financial Trajectory Analysis (2023-2030)

a. Revenue Projections

Year	Estimated Market Size (USD billion)	CAGR	Key Notes
2023	1.25	—	Baseline
2024	1.30	4.0%	Market stabilization
2025	1.36	4.6%	Growth in emerging markets
2026	1.41	4.2%	Novel formulations gain traction
2027	1.48	4.5%	Maturation of segment
2030	1.65	4.8%	Increased penetration, innovation

b. Profitability Outlook

Aspect	2022	2027	Notes
Operating Margin (%)	15%	20%	Improved formulations and market expansion expected to enhance margins
R&D Investment (%)	8-10%	10%	Focused on reducing side-effects and novel delivery systems
Market Penalties	Low	Moderate	Patent expirations and generics impact revenues in mature markets

c. Major Revenue Contributors

Contributor	Share (2022)	Forecast 2027	Notes
Prescription drugs	70%	65%	Decline expected with OTC sales growth
Dietary supplements	30%	35%	Growing due to consumer health trends

6. Competitive Landscape and Key Manufacturers

Company	Market Share (%)	Focus Areas	Notable Products
Abbott Laboratories	20%	Extended-release niacin formulations	Niaspan®
Pfizer (now BioNTech partnership)	15%	Combination lipid therapies	Generic niacin products
BASF (Active Pharmaceutical Ingredients)	10%	Raw material supply and synthesis	Bulk niacin raw materials
Others	55%	Generics and regional players	Various OTC and prescription drugs

7. Comparative Analysis of Related Lipid-Modifying Agents

Agent Type	Efficacy	Side Effects	Market Presence
Niacin (extended-release)	Moderate LDL and TG reduction	Flushing, hepatotoxicity	Moderate
Statins	High LDL reduction	Muscle pain, liver enzyme increase	Dominant
PCSK9 inhibitors	Significant LDL reduction	Injection site reactions	Niche, expanding

8. Regulatory and Policy Environment

Regulatory agencies focus on risk-benefit evaluations, especially regarding side-effects.
Recent guidelines (e.g., American Heart Association, European Society of Cardiology) favor statins but acknowledge adjunctive roles of niacin in select cases.
OTC status varies regionally, influencing market access strategies.

Key Takeaways

Insight	Implication
Market expansion persists, particularly in emerging markets	Companies should target APAC and LATAM regions for growth
Side-effect management and formulation innovation are critical	Investment in advanced delivery systems remains vital
Competition from statins and PCSK9 inhibitors intensifies	Differentiation and niche positioning essential for profitability
Regulatory forces and patent expiry pressures increase	Diversify product pipelines and explore novel compounds
Growing consumer demand in nutraceuticals fuels OTC sales	Brands should expand in direct-to-consumer channels

FAQs

Q1: What are the primary therapeutic uses of niacin today?
A1: Niacin remains primarily used for dyslipidemia management, especially for increasing HDL cholesterol and lowering LDL cholesterol and triglycerides, and as a nutritional supplement for vitamin deficiency prevention.

Q2: How does side-effect profile impact niacin’s market growth?
A2: The adverse effects such as flushing and hepatotoxicity have led clinicians to favor alternative lipid-lowering therapies, causing a decline in prescription volumes and prompting innovation in formulations.

Q3: What are the opportunities for growth in emerging markets?
A3: Increasing health awareness, rising disposable incomes, and expanding healthcare infrastructure drive OTC and prescription sales, providing avenues for market entry and expansion.

Q4: How does the patent landscape affect profitability?
A4: Patent expiries lead to generic competition, reducing margins. Strategies such as developing novel formulations or combination drugs are necessary to sustain profitability.

Q5: What is the outlook for combination therapies involving niacin?
A5: Growth is anticipated as combination therapies aim to enhance efficacy and mitigate side-effects, supported by ongoing research into multi-mechanism lipid management.

References

World Health Organization. (2021). Cardiovascular diseases (CVDs).
MarketWatch. (2022). Niacin Market Size, Share & Trends Analysis Report.
American Heart Association. (2020). Guidelines for Lipid Management.
FDA Approvals. (2021). Extended-release Niacin formulations.
GlobalData. (2022). Strategic Insights on Lipid-Lowering Market.

US Patents:	0
Tradenames:	7
Applicants:	30
NDAs:	37
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	211
Clinical Trials:	182
Drug Prices:	Drug price trends for NIACIN
Drug Sales Revenues:	Drug sales revenues for NIACIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NIACIN
What excipients (inactive ingredients) are in NIACIN?	NIACIN excipients list
DailyMed Link:	NIACIN at DailyMed

NIACIN - Generic Drug Details

What are the generic sources for niacin and what is the scope of freedom to operate?

Summary for NIACIN

Recent Clinical Trials for NIACIN

Pharmacology for NIACIN

Medical Subject Heading (MeSH) Categories for NIACIN

US Patents and Regulatory Information for NIACIN

Expired US Patents for NIACIN

Market Dynamics and Financial Trajectory for Niacin (Vitamin B3)